Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug

The FDA has placed a partial clinical hold on Biohaven's epilepsy drug BHV-7000, pausing new patient enrollment in two late-stage trials due to safety concerns from rodent metabolite findings. This follows previous regulatory setbacks for Biohaven and could delay approval timelines.

This Wire brief sits within Fusion42's coverage of Biotech.